-- Presented preclinical data demonstrating potent activity and favorable
resistance profiles for our non-nucleoside reverse transcriptase
inhibitor (NNRTI) family of compounds against HIV at the 15th Annual
Conference on Retroviruses and Opportunistic Infections (CROI);
-- Presented favorable anti-tumor preclinical data on RDEA119 at the 2007
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics; and
-- Relocated our corporate headquarters and research laboratories to San
Diego's biotechnology corridor.
2008 Anticipated Key Program Milestones
In 2008, Ardea anticipates accomplishing the following milestones:
-- Initiate a Phase 2b trial of RDEA806 in patients with HIV in the
second quarter of 2008;
-- Complete a first-in-human micro-dosing study of our second generation
NNRTI, RDEA427, in the first quarter of 2008;
-- Initiate a Phase 1 trial of RDEA427 in the second half of 2008; and
-- Present the full results of our Phase 2a proof-of-concept study of
RDEA806 at a scientific conference in the second half of 2008.
-- Initiate a Phase 2 dose-finding trial for the treatment of gout in
the second quarter of 2008 with results expected in the second half
of 2008; and
-- Initiate a Phase 2a trial with RDEA119 for the treatment of
inflammatory disease in the second quarter of 2008.
-- Complete and report data from the Phase 1 trial of RDEA119 in
patients with advanced cancer in the second half of 2008;
-- Initiate Phase 2 trials of RDEA119 in combination with other anti
cancer agents in the second half of 2008; and
-- Initiate a Phase 1 trial of our second generation MEK inhibitor in
the second half of 2008.<
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved